Bicycle Therapeutics (BCYC) Competitors $7.99 -0.53 (-6.22%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$8.00 +0.01 (+0.13%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCYC vs. XENE, AGIO, BEAM, ARWR, TWST, HRMY, IDYA, IRON, MESO, and CNTAShould you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include Xenon Pharmaceuticals (XENE), Agios Pharmaceuticals (AGIO), Beam Therapeutics (BEAM), Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), Harmony Biosciences (HRMY), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Mesoblast (MESO), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry. Bicycle Therapeutics vs. Its Competitors Xenon Pharmaceuticals Agios Pharmaceuticals Beam Therapeutics Arrowhead Pharmaceuticals Twist Bioscience Harmony Biosciences IDEAYA Biosciences Disc Medicine Mesoblast Centessa Pharmaceuticals Xenon Pharmaceuticals (NASDAQ:XENE) and Bicycle Therapeutics (NASDAQ:BCYC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership. Which has more volatility and risk, XENE or BCYC? Xenon Pharmaceuticals has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Do insiders & institutionals hold more shares of XENE or BCYC? 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 5.5% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend XENE or BCYC? Xenon Pharmaceuticals currently has a consensus price target of $54.82, suggesting a potential upside of 79.73%. Bicycle Therapeutics has a consensus price target of $24.22, suggesting a potential upside of 203.16%. Given Bicycle Therapeutics' higher probable upside, analysts clearly believe Bicycle Therapeutics is more favorable than Xenon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 3.00Bicycle Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70 Is XENE or BCYC more profitable? Xenon Pharmaceuticals has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -790.07%. Bicycle Therapeutics' return on equity of -25.54% beat Xenon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Xenon PharmaceuticalsN/A -32.44% -30.84% Bicycle Therapeutics -790.07%-25.54%-21.23% Which has better earnings & valuation, XENE or BCYC? Bicycle Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenon Pharmaceuticals$9.43M248.17-$234.33M-$3.23-9.44Bicycle Therapeutics$35.28M15.68-$169.03M-$3.14-2.54 Does the media prefer XENE or BCYC? In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 4 mentions for Xenon Pharmaceuticals and 3 mentions for Bicycle Therapeutics. Xenon Pharmaceuticals' average media sentiment score of 1.71 beat Bicycle Therapeutics' score of 0.34 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Bicycle Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBicycle Therapeutics beats Xenon Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCYC vs. The Competition Export to ExcelMetricBicycle TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$590.04M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-2.5417.6228.6723.80Price / Sales15.68179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book0.708.508.275.55Net Income-$169.03M-$55.06M$3.24B$259.03M7 Day Performance-8.16%-3.98%-3.69%-4.59%1 Month Performance7.39%9.59%4.33%4.46%1 Year Performance-68.41%6.72%25.95%18.03% Bicycle Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCYCBicycle Therapeutics3.4273 of 5 stars$7.99-6.2%$24.22+203.2%-67.2%$590.04M$35.28M-2.54240Upcoming EarningsXENEXenon Pharmaceuticals3.0402 of 5 stars$30.97+2.2%$54.82+77.0%-30.3%$2.33B$9.43M-9.59210News CoveragePositive NewsShort Interest ↑AGIOAgios Pharmaceuticals4.001 of 5 stars$37.20-7.0%$56.33+51.4%-21.3%$2.32B$36.50M3.31390News CoverageEarnings ReportBEAMBeam Therapeutics2.6035 of 5 stars$20.83-4.1%$48.75+134.0%-37.9%$2.18B$63.52M-4.52510Upcoming EarningsInsider TradeGap DownARWRArrowhead Pharmaceuticals3.8283 of 5 stars$16.20+2.9%$43.71+169.8%-42.0%$2.17B$3.55M-11.57400News CoveragePositive NewsUpcoming EarningsTWSTTwist Bioscience3.566 of 5 stars$36.53+1.5%$50.40+38.0%-36.5%$2.16B$312.97M-11.24990News CoverageUpcoming EarningsShort Interest ↑Gap DownHRMYHarmony Biosciences4.7364 of 5 stars$35.76-4.7%$51.00+42.6%+5.1%$2.15B$714.73M13.65200Positive NewsUpcoming EarningsIDYAIDEAYA Biosciences4.0764 of 5 stars$25.02+2.1%$48.09+92.2%-42.8%$2.15B$7M-6.9780Upcoming EarningsHigh Trading VolumeIRONDisc Medicine3.383 of 5 stars$59.48-1.9%$95.73+60.9%+36.3%$2.10BN/A-15.1730Upcoming EarningsInsider TradeGap UpMESOMesoblast1.1658 of 5 stars$15.93-2.6%$18.00+13.0%+141.2%$2.09B$5.90M0.0080Positive NewsCNTACentessa Pharmaceuticals3.0332 of 5 stars$15.20-1.4%$28.10+84.9%+63.4%$2.06B$6.85M-8.40200News CoverageAnalyst ForecastInsider Trade Related Companies and Tools Related Companies Xenon Pharmaceuticals Competitors Agios Pharmaceuticals Competitors Beam Therapeutics Competitors Arrowhead Pharmaceuticals Competitors Twist Bioscience Competitors Harmony Biosciences Competitors IDEAYA Biosciences Competitors Disc Medicine Competitors Mesoblast Competitors Centessa Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCYC) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCYC Stock Alerts